Premium
Double benefit of long‐acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis
Author(s) -
Yarman S.,
Yalın G. Y.,
Dogansen S. C.,
Canbaz B.,
Tanrıkulu S.,
Akyuz F.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12412
Subject(s) - acromegaly , ulcerative colitis , medicine , somatostatin , octreotide , gastroenterology , inflammatory bowel disease , hormone , disease , growth hormone
Summary What is known and objective Somatostatin analogs control GH/IGF‐1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long‐acting octreotide (OCT‐LAR) treatment in terms of both acromegaly and ulcerative colitis (UC). Case summary A 58‐year‐old female patient with diagnosis of acromegaly and ulcerative colitis was started on long‐acting somatostatin treatment as a first‐line treatment for acromegaly as she refused to undergo transsphenoidal surgery. During the follow‐up period, a significant amelioration was also observed in the course of ulcerative colitis, and clinical remission of both diseases was achieved uneventfully. What is new and conclusion Somatostatin appears to be a promising candidate in the treatment of inflammatory bowel diseases.